Finerenone Benefits Patients With T2D, CKD Across CKM Stages

In patients with T2D and CKD, finerenone lowers the risk for adverse cardiovascular and kidney events compared with placebo, regardless of the CKM syndrome stage at baseline.
Medscape Medical News

source https://www.medscape.com/viewarticle/finerenone-benefits-patients-t2d-ckd-across-cardiovascular-2026a1000m3s?src=rss